Abstract:Reactive oxygen species (ROS) and reactive nitrogen species (RNS) play a key role in the regulation of the physiological and pathological signaling within the vasculature. In physiological conditions, a delicate balance between oxidants and antioxidants protects cells from the detrimental effects of ROS/RNS. Indeed, the imbalance between ROS/RNS production and antioxidant defense mechanisms leads to oxidative and nitrosative stress within the cell. These processes promote the vascular damage observed in chronic conditions, such as hypertension. The strong implication of ROS/RNS in the etiology of hypertension suggest that antioxidants could be effective in the treatment of this pathology. Indeed, in animal models of hypertension, the overexpression of antioxidants and the genetic modulation of oxidant systems have provided an encouraging proof of concept. Nevertheless, the translation of these strategies to human disease did not reach the expected success. This could be due to the complexity of this condition, whose etiology depends on multiple factors (smoking, diet, life styles, genetics, family history, comorbidities). Indeed, 95% of reported high blood pressure cases are deemed "essential hypertension," and at the molecular level, oxidative stress seems to be a common feature of hypertensive states. In this scenario, new therapies are emerging that could be useful to reduce oxidative stress in hypertension. It is now ascertained the role of Vitamin D deficiency in the development of essential hypertension and it has been shown that an appropriate high dose of Vitamin D significantly reduces blood pressure in hypertensive cohorts with vitamin D deficiency. Moreover, new drugs are emerging which have both antihypertensive action and antioxidant properties, such as celiprolol, carvedilol, nebivolol. Indeed, besides adrenergic desensitization, these kind of drugs are able to interfere with ROS/RNS generation and/or signaling, and are therefore considered promising therapeutics in the management of hypertension. In the present review we have dealt with the effectiveness of the antioxidant therapy in the management of hypertension. In particular, we discuss about Vitamin D and anti-hypertensive drugs with antioxidant properties.

New therapeutic targets in hypertension

New and developing pharmacotherapies for hypertension

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

New Molecules for Treating Resistant Hypertension: a Clinical Perspective

Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

Beyond ACE inhibition: new developments in drug therapy for hypertension

Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach

The new progress in treatment of hypertension

Present and future of drug therapy in hypertension: an overview

New Potential Treatments for Resistant Hypertension

Purinergic Receptor Antagonists: A Complementary Treatment for Hypertension

Resolvin D1 as a novel target in the management of hypertension

Advances in the Treatment Strategies in Hypertension: Present and Future

Pharmacological Research Progress of Novel Antihypertensive Drugs

Hypertension and Heart Failure: From Pathophysiology to Treatment

Plant-food-derived Bioactives in Managing Hypertension: From Current Findings to Upcoming Effective Pharmacotherapies

Innovative hypertension treatments: transitioning from conventional therapies to siRNA-based solutions

Current and future strategies for targeting the endothelin pathway in cardiovascular disease

The Antioxidant Therapy: New Insights in the Treatment of Hypertension

The Increasing Problem of Resistant Hypertension: We'll Manage till Help Comes!